Risperidone augmentation in refractory obsessive-compulsive disorder: An open-label study

C. Pfanner, D. Marazziti, L. Dell'Osso, S. Presta, A. Gemignani, A. Milanfranchi, G. B. Cassano

Research output: Contribution to journalArticlepeer-review


Risperidone, an atypical neuroleptic, has been proposed for augmentation strategies in resistant obsessive-compulsive disorder (OCD). We report the results of an open-label trial on the use of the combination of serotonin reuptake inhibitors (SRIs) with risperidone in 20 refractory OCD outpatients. All patients had been suffering from OCD, according to DSM-IV criteria, for at least 2 years and had various comorbid disorders. All had been treated with a SRI at adequate dosages for at least 6 months, but had failed to respond. Therefore, risperidone was added and the dosage titrated up to the mean dose of 3 mg/day over 8 weeks. After 2 months of this regimen, all patients had shown a reduction in obsessive-compulsive symptoms, as assessed by the decrease in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) total score, particularly those with a lifetime comorbidity with bipolar disorder; only three patients reported mild sedation and postural hypotension, two mild extrapyramidal side-effects (tremors and akatysia) and two an increased appetite. All these effects were well tolerated and no patient halted the treatment. The addition of risperidone would appear to be a useful strategy for augmenting SRI effectiveness in refractory OCD patients. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalInternational Clinical Psychopharmacology
Issue number5
Publication statusPublished - 2000


  • Atypical neuroleptics
  • Augmentation strategies
  • Obsessive-compulsive disorder
  • Risperidone
  • Serotonin reuptake inhibitors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Risperidone augmentation in refractory obsessive-compulsive disorder: An open-label study'. Together they form a unique fingerprint.

Cite this